Details of Disease

General Information of Disease (ID: DISFKGJU)

• Disease Name: Idiopathic thrombocytopenic purpura
• Synonyms: immune thrombocytopenic purpura; AITP; idiopathic purpura; thrombocytopenic purpura autoimmune; ideopath thrombocytopenic pur; Werlhof's disease; primary thrombocytopenic purpura; idiopathic thrombocytopenia purpura; immune thrombocytopenia; autoimmune thrombocytopenic purpura; idiopathic thrombocytopenia; ITP; idiopathic thrombocytopenic purpura; thrombocytopenic purpura, autoimmune
• Disease Class: 3B64: Thrombocytopenia
• Definition: An autoimmune disorder in which the number of circulating platelets is reduced due to their antibody-mediated destruction. ITP is a diagnosis of exclusion and is heterogeneous in origin.
• Disease Hierarchy:
  DISZI5Z8: Thrombocytopenic purpura
  DIS5GLM9: Primary thrombocytopenia
  DIS1DL2M: Inherited blood coagulation disorder
  DISANU9Q: Inherited thrombocytopenia
  DISNF0OI: Autoimmune thrombocytopenia
  DISIUNXT: Inherited bleeding disorder, platelet-type
  DISFKGJU: Idiopathic thrombocytopenic purpura
• ICD Code:
  ICD-11: ICD-11: 3B64.10
  ICD-10: ICD-10: D69, D69.3
• Disease Identifiers:
  MONDO ID: MONDO_0008558
  MESH ID: D016553
  UMLS CUI: C0398650
  OMIM ID: 188030
  MedGen ID: 584986
  Orphanet ID: 3002

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AS-1670542	DMV05SW	Approved	Small molecular drug	[1]
Eltrombopag	DMOGFIX	Approved	Small molecular drug	[2]
GMA-161	DMGVJLB	Approved (orphan drug)	NA	[3]
Rituximab	DM1YVZT	Approved	Antibody	[4]
SM-101	DMFX9O6	Approved (orphan drug)	Small molecular drug	[3]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BT595	DM2EC8A	Phase 3	Protein	[5]
Sc Veltuzumab	DM2S8W3	Phase 1	Monoclonal antibody	[6]

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RhTPO	DMCV0BZ	Discontinued in Phase 3	NA	[3]
BR3-Fc	DMFN1WI	Discontinued in Phase 2	NA	[3]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Anti-D	DMG7PC0	Investigative	Small molecular drug	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 39 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
TNFSF13B	TTWMIDN	Limited	Altered Expression	[8]
CTLA4	TTI2S1D	moderate	Altered Expression	[9]
ADAMTS13	TTUREBK	Strong	Biomarker	[10]
ADRB3	TTMXGCW	Strong	Altered Expression	[11]
AHCY	TTE2KUJ	Strong	Biomarker	[12]
APOH	TT2OUI9	Strong	Biomarker	[13]
CD69	TTPQE9F	Strong	Altered Expression	[14]
CD83	TTT9MRQ	Strong	Biomarker	[15]
CD86	TT53XHB	Strong	Biomarker	[15]
CXCL13	TT0NIZ1	Strong	Biomarker	[16]
DDX5	TTZKPVC	Strong	Biomarker	[17]
FCER1G	TTDGEC0	Strong	Biomarker	[18]
FCGR1A	TTZK4I3	Strong	Altered Expression	[19]
FCGRT	TTKLPHO	Strong	Biomarker	[20]
GEM	TTAZF9M	Strong	Genetic Variation	[21]
GP1BA	TTVB0Q9	Strong	Altered Expression	[22]
GP6	TTTJUVZ	Strong	Biomarker	[23]
IL11	TTGUYTR	Strong	Biomarker	[24]
IL17F	TT2B6PS	Strong	Genetic Variation	[25]
IL21	TT9QEJ6	Strong	Altered Expression	[26]
IL22	TTLDX4N	Strong	Altered Expression	[27]
ITGB3	TTJA1ZO	Strong	Biomarker	[28]
KIR2DL2	TTU0P73	Strong	Biomarker	[29]
KIR2DL3	TTEX3SI	Strong	Altered Expression	[29]
KIR2DS2	TTV3CFI	Strong	Biomarker	[29]
KIR3DL2	TTQH3N0	Strong	Biomarker	[21]
LTA	TTP73TM	Strong	Genetic Variation	[30]
MS4A1	TTUE541	Strong	Biomarker	[31]
RHD	TTLCKI8	Strong	Biomarker	[32]
SELP	TTE5VG0	Strong	Biomarker	[33]
STAT1	TTN7R6K	Strong	Genetic Variation	[34]
SYK	TT2HUPM	Strong	Biomarker	[35]
TCIRG1	TTVRN05	Strong	Biomarker	[36]
THPO	TTCG5PE	Strong	Biomarker	[37]
TNFRSF13C	TT7NJSE	Strong	Altered Expression	[38]
TNFRSF17	TTZ3P4W	Strong	Altered Expression	[38]
TNFSF13	TTOI1RM	Strong	Biomarker	[39]
ICOS	TTE5VP6	Definitive	Biomarker	[40]
TNFRSF13B	TTL9OD4	Definitive	Genetic Variation	[41]

This Disease Is Related to 37 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ACSBG1	OTM040MW	Limited	Biomarker	[42]
RAPH1	OTMQXW7S	Limited	Biomarker	[42]
ACTN1	OTUCLNXH	Strong	Genetic Variation	[43]
CD72	OTPOJID2	Strong	Altered Expression	[44]
CLEC1B	OTO38TRG	Strong	Biomarker	[23]
CUL9	OTPUCLZT	Strong	Biomarker	[45]
GATA2	OTBP2QQ2	Strong	Altered Expression	[46]
GCHFR	OTEOT8GI	Strong	Altered Expression	[47]
GFI1B	OTRDW8YO	Strong	Genetic Variation	[48]
GP5	OT3WGPR3	Strong	Biomarker	[49]
GP9	OTA19OKO	Strong	Altered Expression	[50]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[9]
HLA-DRB3	OT5PM9N7	Strong	Genetic Variation	[51]
HOXB4	OTH1HRW5	Strong	Altered Expression	[46]
HOXD13	OTWSC8TF	Strong	Biomarker	[52]
IL10RA	OTOX3D1D	Strong	Genetic Variation	[53]
IL18BP	OTW0LRYZ	Strong	Altered Expression	[54]
ITGA2B	OT4Y17PY	Strong	Altered Expression	[55]
KIR2DS3	OT3PSLDL	Strong	Genetic Variation	[29]
KIR2DS5	OTXLEN11	Strong	Biomarker	[29]
KIR3DL1	OTPOSXFX	Strong	Genetic Variation	[21]
KLRD1	OTMYLOV4	Strong	Biomarker	[56]
KRT20	OT4RB40L	Strong	Biomarker	[31]
MAP6	OTPUI00F	Strong	Genetic Variation	[57]
MSC	OTBRPZL5	Strong	Biomarker	[58]
NAP1L1	OTI7WBZV	Strong	Altered Expression	[59]
OPTN	OT2UXWH9	Strong	Altered Expression	[59]
PRB2	OTAD4JZ0	Strong	Biomarker	[60]
RNF112	OT0Q9OUQ	Strong	Biomarker	[61]
RO60	OTLGM5A8	Strong	Biomarker	[62]
SCAMP1	OTFS4IKJ	Strong	Biomarker	[63]
SCAMP2	OTFGSCHQ	Strong	Biomarker	[63]
SLC7A4	OTAVC6QS	Strong	Biomarker	[64]
TBXT	OTHCO2F0	Strong	Altered Expression	[65]
TRIT1	OTCU9FS5	Strong	Biomarker	[66]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[67]
SIAH2	OTKED2XN	Definitive	Altered Expression	[68]

References

• [1] ClinicalTrials.gov (NCT01433978) A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). U.S. National Institutes of Health.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6961).
• [3] Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
• [4] Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease. Rom J Intern Med. 2019 Dec 1;57(4):273-283.
• [5] Clinical pipeline report, company report or official report of Biotest Pharmaceuticals.
• [6] Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab: a phase I study in chronic lymphocytic leukemia. Leuk Lymphoma. 2015 Oct 19:1-9.
• [7] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022291.
• [8] Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP).Clin Immunol. 2018 Mar;188:74-80. doi: 10.1016/j.clim.2017.12.010. Epub 2017 Dec 26.
• [9] Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children.Hematology. 2019 Dec;24(1):123-128. doi: 10.1080/10245332.2018.1530179. Epub 2018 Oct 14.
• [10] Is it quinine TTP/HUS or quinine TMA? ADAMTS13 levels and implications for therapy.J Clin Apher. 2009;24(3):115-9. doi: 10.1002/jca.20194.
• [11] Dysregulated megakaryocyte distribution associated with nestin(+) mesenchymal stem cells in immune thrombocytopenia.Blood Adv. 2019 May 14;3(9):1416-1428. doi: 10.1182/bloodadvances.2018026690.
• [12] Decreased DNA methyltransferase 3A and 3B mRNA expression in peripheral blood mononuclear cells and increased plasma SAH concentration in adult patients with idiopathic thrombocytopenic purpura.J Clin Immunol. 2008 Sep;28(5):432-9. doi: 10.1007/s10875-008-9223-2. Epub 2008 Aug 6.
• [13] Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.Hematology. 2019 Dec;24(1):134-138. doi: 10.1080/10245332.2018.1532649. Epub 2018 Oct 25.
• [14] Increased ADAM10 expression in patients with immune thrombocytopenia.Int Immunopharmacol. 2018 Feb;55:63-68. doi: 10.1016/j.intimp.2017.12.004. Epub 2017 Dec 22.
• [15] High dose dexamethasone as an alternative rescue therapy for active bleeding in children with chronic ITP: clinical and immunological effects.Platelets. 2019;30(7):886-892. doi: 10.1080/09537104.2018.1530347. Epub 2018 Oct 22.
• [16] Long non-coding RNA MEG3 inhibits microRNA-125a-5p expression and induces immune imbalance of Treg/Th17 in immune thrombocytopenic purpura.Biomed Pharmacother. 2016 Oct;83:905-911. doi: 10.1016/j.biopha.2016.07.057. Epub 2016 Aug 10.
• [17] Elucidation of the Mechanisms and Molecular Targets of Yiqi Shexue Formula for Treatment of Primary Immune Thrombocytopenia Based on Network Pharmacology.Front Pharmacol. 2019 Oct 1;10:1136. doi: 10.3389/fphar.2019.01136. eCollection 2019.
• [18] An (II)(b) (3) antagonist prevents thrombosis without causing Fc receptor -chain IIa-mediated thrombocytopenia.J Thromb Haemost. 2017 Nov;15(11):2230-2244. doi: 10.1111/jth.13803. Epub 2017 Oct 9.
• [19] Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating Fc receptors.Int J Hematol. 2017 May;105(5):598-605. doi: 10.1007/s12185-016-2172-2. Epub 2016 Dec 27.
• [20] Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.Am J Hematol. 2020 Feb;95(2):178-187. doi: 10.1002/ajh.25680. Epub 2019 Dec 10.
• [21] A Study of Human Killer Cell Immunoglobulin-Like Receptor and Multidrug Resistance Gene Polymorphisms in Children With Immune Thrombocytopenia.Clin Appl Thromb Hemost. 2016 Jul;22(5):429-40. doi: 10.1177/1076029615576738. Epub 2015 Mar 18.
• [22] Increased GPIb shedding from platelets treated with immune thrombocytopenia plasma.Int Immunopharmacol. 2019 Jan;66:91-98. doi: 10.1016/j.intimp.2018.11.011. Epub 2018 Nov 13.
• [23] Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.Thromb Haemost. 2018 Jun;118(6):1009-1020. doi: 10.1055/s-0038-1646924. Epub 2018 Apr 25.
• [24] Platelet and peripheral white blood cell counts at diagnosis predict the response of adult immune thrombocytopenia to recombinant human interleukin-11: A retrospective, single-center, case-control study.Medicine (Baltimore). 2019 Apr;98(16):e15195. doi: 10.1097/MD.0000000000015195.
• [25] Assessment of IL-17F rs763780 gene polymorphism in immune thrombocytopenia.Blood Cells Mol Dis. 2019 Mar;75:20-25. doi: 10.1016/j.bcmd.2018.12.001. Epub 2018 Dec 14.
• [26] Clinical significance and immunobiology of IL-21 in autoimmunity.J Autoimmun. 2019 May;99:1-14. doi: 10.1016/j.jaut.2019.01.013. Epub 2019 Feb 14.
• [27] The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpura.Int Immunopharmacol. 2019 Aug;73:181-192. doi: 10.1016/j.intimp.2019.04.061. Epub 2019 May 16.
• [28] Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy.Cancer Cell Int. 2019 Mar 15;19:59. doi: 10.1186/s12935-019-0779-0. eCollection 2019.
• [29] The presence of KIR2DS5 confers protection against adult immune thrombocytopenia.Tissue Antigens. 2014 Mar;83(3):154-60. doi: 10.1111/tan.12295. Epub 2014 Feb 12.
• [30] The potential association of tumor necrosis factor-eta (252 G/A) cytokine gene polymorphism with immune thrombocytopenic purpura among Egyptian children.Hematology. 2018 Jun;23(5):299-303. doi: 10.1080/10245332.2017.1386429. Epub 2017 Oct 12.
• [31] Anterior ST-elevation myocardial infarction induced by rituximab infusion: A case report and review of the literature.J Clin Pharm Ther. 2017 Jun;42(3):356-362. doi: 10.1111/jcpt.12522.
• [32] RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia.Pediatr Blood Cancer. 2013 Sep;60(9):E106-8. doi: 10.1002/pbc.24574. Epub 2013 May 27.
• [33] Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia.Platelets. 2019;30(2):206-212. doi: 10.1080/09537104.2017.1394451. Epub 2017 Dec 7.
• [34] STAT1 single nucleotide polymorphisms and susceptibility to immune thrombocytopenia.Autoimmunity. 2015;48(5):305-12. doi: 10.3109/08916934.2015.1016218. Epub 2015 Feb 24.
• [35] Fostamatinib for the treatment of immune thrombocytopenia in adults.Am J Health Syst Pharm. 2019 May 17;76(11):789-794. doi: 10.1093/ajhp/zxz052.
• [36] Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia.Hematology. 2014 Dec;19(8):477-82. doi: 10.1179/1607845414Y.0000000156. Epub 2014 Mar 11.
• [37] Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.Eur J Haematol. 2019 May;102(5):416-423. doi: 10.1111/ejh.13221. Epub 2019 Mar 7.
• [38] Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia.Br J Haematol. 2014 Sep;166(5):783-91. doi: 10.1111/bjh.12958. Epub 2014 May 30.
• [39] B-cell-activating factor, a proliferation inducing ligand and co-stimulatory molecules in the pathogenesis of immune thrombocytopenia in childhood.Blood Coagul Fibrinolysis. 2016 Jul;27(5):494-9. doi: 10.1097/MBC.0000000000000144.
• [40] Adult Primary Immune Thrombocytopenia: Spleen Histology Findings and Outcomes According to Rituximab Use Based on Analysis of 41 Cases.Am J Surg Pathol. 2018 Mar;42(3):401-412. doi: 10.1097/PAS.0000000000000994.
• [41] A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia.J Thromb Haemost. 2017 Nov;15(11):2259-2269. doi: 10.1111/jth.13806. Epub 2017 Sep 13.
• [42] Use of eltrombopag for patients 65years old or older with immune thrombocytopenia.Eur J Haematol. 2020 Mar;104(3):259-270. doi: 10.1111/ejh.13370. Epub 2020 Feb 3.
• [43] Familial macrothrombocytopenia due to a double mutation in cis in the alpha-actinin 1 gene (ACTN1), previously considered to be chronic immune thrombocytopenic purpura.Pediatr Blood Cancer. 2018 Dec;65(12):e27418. doi: 10.1002/pbc.27418. Epub 2018 Aug 19.
• [44] Upregulation of CD72 expression on CD19(+) CD27(+) memory Bcells by CD40L in primary immune thrombocytopenia.Br J Haematol. 2017 Jul;178(2):308-318. doi: 10.1111/bjh.14671. Epub 2017 Apr 17.
• [45] Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition?.Pediatr Blood Cancer. 2006 Oct 15;47(5 Suppl):678-80. doi: 10.1002/pbc.21005.
• [46] Gene expression profiling identifies HOXB4 as a direct downstream target of GATA-2 in human CD34+ hematopoietic cells.PLoS One. 2012;7(9):e40959. doi: 10.1371/journal.pone.0040959. Epub 2012 Sep 24.
• [47] Decreased IL-35 levels in patients with immune thrombocytopenia.Hum Immunol. 2014 Aug;75(8):909-13. doi: 10.1016/j.humimm.2014.06.019. Epub 2014 Jun 30.
• [48] Macrothrombocytopenia associated with a rare GFI1B missense variant confounding the presentation of immune thrombocytopenia.Pediatr Blood Cancer. 2019 Sep;66(9):e27874. doi: 10.1002/pbc.27874. Epub 2019 Jun 17.
• [49] Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia.Haematologica. 2019 Jun;104(6):1237-1243. doi: 10.3324/haematol.2018.211086. Epub 2019 Mar 28.
• [50] A novel mutation in the GP1BA gene in Bernard-Soulier syndrome.Blood Coagul Fibrinolysis. 2020 Jan;31(1):83-86. doi: 10.1097/MBC.0000000000000868.
• [51] Pregnancy-associated autoimmune neonatal thrombocytopenia: role of maternal HLA genotype.Br J Haematol. 1999 Mar;104(4):878-85. doi: 10.1046/j.1365-2141.1999.01270.x.
• [52] PD-1/PD-L1 pathway activation restores the imbalance of Th1/Th2 and treg/Th17 cells subtypes in immune thrombocytopenic purpura patients.Medicine (Baltimore). 2019 Oct;98(43):e17608. doi: 10.1097/MD.0000000000017608.
• [53] Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease: a case report.BMC Gastroenterol. 2016 Jan 28;16:10. doi: 10.1186/s12876-016-0424-5.
• [54] Detection of expression of IL-18 and its binding protein in Egyptian pediatric immune thrombocytopenic purpura.Platelets. 2014;25(3):193-6. doi: 10.3109/09537104.2013.784734. Epub 2013 Apr 4.
• [55] Antigenic Mimicry in Paraneoplastic Immune Thrombocytopenia.Front Immunol. 2019 Mar 22;10:523. doi: 10.3389/fimmu.2019.00523. eCollection 2019.
• [56] NK cell compartment in the peripheral blood and spleen in adult patients with primary immune thrombocytopenia.Clin Immunol. 2017 Apr;177:18-28. doi: 10.1016/j.clim.2015.11.005. Epub 2015 Nov 18.
• [57] FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.MAbs. 2012 Nov-Dec;4(6):784-7. doi: 10.4161/mabs.22287. Epub 2012 Oct 2.
• [58] CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia.Int J Mol Sci. 2019 Feb 28;20(5):1049. doi: 10.3390/ijms20051049.
• [59] Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression.Int Immunopharmacol. 2019 Jul;72:437-444. doi: 10.1016/j.intimp.2019.04.041.
• [60] Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia.Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10682-E10691. doi: 10.1073/pnas.1808217115. Epub 2018 Oct 18.
• [61] Biologic false-positive serologic tests for syphilis and other serologic abnormalities in autoimmune hemolytic anemia and thrombocytopenic purpura.Medicine (Baltimore). 1989 Mar;68(2):67-84. doi: 10.1097/00005792-198903000-00001.
• [62] Thrombocytopenia in the neonatal lupus syndrome.Arch Dermatol. 1988 Apr;124(4):560-3.
• [63] Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP() ).Pediatr Blood Cancer. 2017 May;64(5):10.1002/pbc.26303. doi: 10.1002/pbc.26303. Epub 2016 Oct 26.
• [64] Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation.Blood. 2002 Aug 15;100(4):1388-98.
• [65] Aberrant expression of RUNX3 in patients with immune thrombocytopenia.Int Immunopharmacol. 2015 Sep;28(1):252-6. doi: 10.1016/j.intimp.2015.06.008. Epub 2015 Jun 17.
• [66] Profiling of miRNA expression in immune thrombocytopenia patients before and after Qishunbaolier (QSBLE) treatment.Biomed Pharmacother. 2015 Oct;75:196-204. doi: 10.1016/j.biopha.2015.07.022. Epub 2015 Aug 18.
• [67] CNR2 functional variant (Q63R) influences childhood immune thrombocytopenic purpura.Haematologica. 2011 Dec;96(12):1883-5. doi: 10.3324/haematol.2011.045732. Epub 2011 Aug 9.
• [68] The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.Leuk Res. 2016 Mar;42:28-36. doi: 10.1016/j.leukres.2016.01.013. Epub 2016 Jan 28.